deltatrials
Approved For Marketing NCT00377065

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options

Sponsor: Merck Sharp & Dohme LLC

Conditions HIV Infections
Interventions raltegravir
Updated 8 times since 2017 Last updated: Apr 21, 2016

A observational or N/A phase clinical study on HIV Infections, this trial is ongoing. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 8 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Approved For Marketing

  2. Jul 2024 — Sep 2024 [monthly]

    Approved For Marketing

  3. Jun 2022 — Jul 2024 [monthly]

    Approved For Marketing

  4. Jan 2021 — Jun 2022 [monthly]

    Approved For Marketing

  5. Jun 2018 — Jan 2021 [monthly]

    Approved For Marketing

▶ Show 3 earlier versions

  1. Apr 2018 — Jun 2018 [monthly]

    Approved For Marketing

    Phase: NA → None

  2. Feb 2017 — Apr 2018 [monthly]

    Approved For Marketing NA

  3. Jan 2017 — Feb 2017 [monthly]

    Approved For Marketing NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.